Obesity in T1D; Caloric Restriction to Slow Aging? Novo Nordisk Apologies

Adults with type 1 diabetes (T1D) with overweight or obesity were less likely to receive lifestyle recommendations from providers compared with adults with type 2 diabetes, according to an Annals of Internal Medicine research letter.

The FDA warned consumers not to purchase Alfia weight loss capsules due to cardiovascular concerns with the ingredient sibutramine.

A 25% calorie-restricted diet for 2 years slowed the pace of aging by about 3% compared with a normal diet. “Our findings are important because they provide evidence from a randomized trial that slowing human aging may be possible,” said study co-author Calen Ryan, PhD, of Columbia University’s Butler Aging Center in New York City. (Nature Aging)

Independent of food intake, exercising in the late morning burned more fat than late evening exercise — at least in mice. (PNAS)

Scientists linked a group of microRNAs in pancreatic cells with the development of type 2 diabetes. “The results of this study set the stage for understanding how microRNAs fine-tune gene expression in pancreatic islets and its implications for diabetes,” said study author Francis Collins, MD, PhD, of the NIH. (PNAS)

Novo Nordisk issued a formal apology after failing to disclosure sponsorship of an obesity training course that promoted its drug liraglutide (Saxenda). (Financial Times)

Have rising insulin costs created a black market for diabetes supplies? (NBC News)

Handgrip strength in postmenopausal women was modestly linked with follicle-stimulating hormone, cortisol, and dehydroepiandrosterone sulfate, but not with ovarian steroids, adrenal hormones, IGF-1, parathormone, or vitamin D levels. (Menopause)

South Dakota Gov. Kristi Noem (R) signed a bill prohibiting gender-affirming care for transgender kids, as more and more Conservative state lawmakers continue to advance bills to prohibit gender-affirming treatments for trans youth. (AP)

Low-normal thyroid function was tied to a significantly higher risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease. (BMC Gastroenterology)